Mesa Laboratories stock
MLABNASDAQMesa Laboratories, Inc., HealthcareISIN US59064R1095
58Score 58 out of 100, Neutral
Price and trend
88 / 100
Price history
+69% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 27% above it.
Since February 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 56).
The price is 4.9% below its 52-week high. Largest decline in 20 years: 83% (December 2021 to August 2025).
Chart figures for advanced users
- SMA 50$128.82
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$106.19
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)56
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$70.60
- The lowest closing price of the last twelve months.
- Resistance$142.23
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Mesa Laboratories, Inc. belongs to the Medical (Specialties) industry (United States) and, with a market value of $759.89M, is number 9 of 14 companies in its industry on MEQIRI.
- MEQIRI Score 58 out of 100 (Neutral): rank 306 of 714 in Healthcare, median 53.
- The P/E is 116.8 (Healthcare sector median 26.7, own median of recent years 72.5).
Show more
- Our model puts fair value at $90.48, with the price 54% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow above 500% of earnings over the last 12 months.Fundamentals 66
- Reliable dividendNo dividend cut for 20 years.
- Earnings per share growingUp 13.1% a year since 2021.Growth 69
Weaknesses
- Richly valuedP/E 116.8, Healthcare sector median 26.7, own median 72.5.Valuation 24
- Interest barely coveredOperating profit covers interest only 2.1 times.Stability 55
- Volatile share priceVolatility 54% a year over the last 12 months.Stability 55
Its standout strengths are momentum and technical analysis, while valuation and capital allocation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- price up very strongly over the past year
What lowers it
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Modestly overvaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $64.63 and expensive above $150.80 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $150.05 (cash-flow model) and $30.92 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $77.92, at 7.8% it would be $109.33.
Valuation metrics
Half from the cash-flow model, half from earnings times the sector P/E (26.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 2.5% on the twelve months before. Revenue has grown strongly since 2007, at around 15% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 64%, operating 7%, net 3%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 3 Feb 2027in 83 days
- Last reported
- 9 Nov 2026EPS reported $1.80 (expected $2.29)below expectations
Analyst estimates
- Earnings per share
- $10.70+5.0%
- Revenue
- $254.85M+0.2%
- Earnings per share
- $11.02+1.2%
- Revenue
- $266.1M−1.8%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +8.4%No full year guidance yet, it will come in November; the BPD business is expected to grow for the full year, and the new Gyrolab platform is expected in fiscal 2028.
“We reprioritized our R&D portfolio to concentrate investment on this launch, and we now expect the new Gyrolab platform to launch in fiscal 2028.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 10 Aug 2026 (fiscal Q1 2027), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
2 insiders bought on the open market in the last 6 months, $902,411 in total. 4 insiders sold, $1.57M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Sullivan John JamesSale
13 Aug 2026, Board
- Shares
- 7,093
- Price
- $112.80
- Value
- $800,090
- Kadia SiddharthaPurchase
13 Aug 2026, President and CEO
- Shares
- 7,093
- Price
- $112.80
- Value
- $800,090
- Tripeny R TonyPurchase
13 Aug 2026, Board
- Shares
- 900
- Price
- $113.69
- Value
- $102,321
Show 6 more
- Crennen Lyndsey ElizabethSale
22 Jun 2026, CAO
- Shares
- 442
- Price
- $89.50
- Value
- $39,560
- Archbold Brian DavidSale
22 Jun 2026, SVP Operations
- Shares
- 2,516
- Price
- $89.50
- Value
- $225,187
- Sakys JohnSale
22 Jun 2026, CFO
- Shares
- 2,827
- Price
- $89.50
- Value
- $253,022
- Archbold Brian DavidSale
16 Jun 2026, SVP Operations
- Shares
- 1,151
- Price
- $101.27
- Value
- $116,558
- Crennen Lyndsey ElizabethSale
16 Jun 2026, CAO
- Shares
- 118
- Price
- $101.27
- Value
- $11,950
- Sakys JohnSale
16 Jun 2026, CFO
- Shares
- 1,223
- Price
- $101.27
- Value
- $123,850
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Mesa Laboratories
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 58
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Specialties)
The next larger and next smaller companies by market value
- Ypsomed HoldingYPSN.SW $6.56B76
- Medacta GroupMOVE.SW $2.64B58
- Eckert & ZieglerEUZ.DE $969.93M74
- QuidelOrthoQDEL $817.18M32
- Shoulder InnovationsSI $458.61M48
- Mobia MedicalMOBI $448.43M45
- BrainsWayBWAY $440.87M60
- 908 DevicesMASS $415.82M43
ETFs that hold Mesa Laboratories
Held by 6 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Genomics & Biotechnology UCITS ETFGN0M | 0.26% | 0.50% | €127.06M |
| iShares Smart City Infrastructure UCITS ETFAYEU | 0.10% | 0.40% | €343.1M |
| iShares Automation & Robotics UCITS ETF2B76 | 0.04% | 0.40% | €4.49B |
Show 2 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.03% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.02% | 0.30% | €2.17B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 3 Apr 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.